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Abstract
Background: To clarify the immunological alterations leading to classical Kaposi sarcoma (cKS) among people
infected with KS-associated herpesvirus (KSHV).
Methods: In a population-based study of 119 cKS cases, 105 KSHV-seropositive controls, and 155 KSHV-
seronegative controls, we quantified plasma soluble cluster of differentiation (sCD) levels and antibodies against
Epstein-Barr virus nuclear antigen-1 (anti-EBNA-1) and viral capsid antigen (anti-VCA). Differences between groups
in prevalence of low-tertile anti-EBNA-1 and high-tertile anti-VCA were compared by logistic regression. Continuous
levels between groups and by presence of cKS co-factors among controls were compared by linear regression and
Mann-Whitney-Wilcoxon methods.
Results: Comparisons of cKS cases to seropositive controls and of seropositive to seronegative controls revealed
no significant differences. However, controls with known cKS cofactors (male sex, nonsmoking, diabetes and
cortisone use) had significantly lower levels of anti-EBNA (P = 0.0001 - 0.07) and anti-VCA (P = 0.0001 - 0.03). Levels
of sCD26 were significantly lower for male and non-smoking controls (Padj ≤ 0.03), and they were marginally lower
with older age and cortisone use (Padj ≤ 0.09).
Conclusions: Anti-EBV and sCD26 levels were associated with cofactors for cKS, but they did not differ between
cKS cases and matched controls. Novel approaches and broader panels of assays are needed to investigate
immunological contributions to cKS.
Background
Kaposi sarcoma (KS) develops in develops in a minority
of people who have been infected with Kaposi sarcoma-
associated herpesvirus (KSHV). KS is the predominant
malignancy occurring in people with the acquired immu-
nodeficiency syndrome (AIDS), illustrating that cell-
mediated immunity modifies the risk KS. However, the
abnormalities with AIDS are so varied in type and sever-
ity that dissecting those specifically associated with KS is
challenging. Studies of people who do not have overt
immunologic abnormalities may be more informative,
although consistent, unambiguous perturbations have yet
to be reported in non-AIDS KS [1-4].
KSHV reactivation with viremia is predictive for KS [5],
but study of the underlying immunologic mechanisms is
technically difficult and unsettled [6-8]. In lieu of a
KSHV-specific approach, generic measures of immunity
may be helpful. Loss of immunologic control of the
related gammaherpesvirus, Epstein-Barr virus (EBV),
results in viral reactivation and is marked by higher anti-
bodies against viral capsid antigen (anti-VCA) and lower
antibodies against nuclear antigen-1 (anti-EBNA-1). This
EBV serology pattern, as well as altered levels of soluble
cluster of differentiation (sCD) markers (sCD26, sCD23
and sCD30), have been associated with immune-
mediated clinical conditions [9-14]. The Th1/Th2 cellular
immunity paradigm has been the rationale [9-14]. We
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classical KS (cKS) in a population-based study in Sicily.
Results
We included 119 cKS cases, 105 KSHV seropositive
controls, and 155 KSHV seronegative controls (Table 1).
Anti-EBNA-1 levels ranged from 0.59 - 9.59, and anti-
VCA from 0.87 - 9.47. High-tertile anti-VCA was asso-
ciated with KSHV seropositivity among controls (Table
2, lower panel), but overall anti-EBV levels were not
correlated with anti-KSHV levels (Pearson R ≤ 0.07,
P≥0.29). Radiation and chemotherapy history in cases
was infrequent and unrelated to anti-EBV and sCD
levels. Excluding such cases did not substantially alter
the results (data not shown).
Mean [standard deviation (SD)] anti-EBNA-1 levels
were 5.39 (SD 1.93) in cases, 5.56 (SD 1.72) in seroposi-
tive controls, and 5.25 (SD 1.78) in seronegative con-
trols. Mean anti-VCA levels were 5.53 (SD 1.68) in
cases, 5.71 (SD 1.82) in seropositive controls, and 5.40
(SD 1.69) in seronegative controls. Adjusted for age and
sex, mean differences between cases and seropositive
controls were -0.23 [95% confidence interval (CI): -0.70,
0.24] for anti-EBNA-1 and -0.25 (95% CI: -0.72, 0.22)
for anti-VCA. With further adjustment for cKS cofac-
tors, anti-EBV levels were virtually identical (mean
difference 0.02 for anti-EBNA-1, 0.03 for anti-VCA).
Anti-EBV levels did not confound or modify the associa-
tions of the cofactors with cKS (data not presented)
[15]. Only 5 cases and 6 seropositive controls had low-
EBNA-1/high-VCA, which was associated with a non-
significantly lower risk of cKS (Table 2, upper panel).
Comparing KSHV-seropositive versus -seronegative
controls, adjusted for age and sex, mean differences
were 0.34 (95% CI: -0.11, 0.80) for both anti-EBNA-1
and anti-VCA. With further adjustment for cKS cofac-
tors, mean differences were 0.21 (95% CI: -0.24, 0.66)
and 0.18 (95% CI: -0.26, 0.62) for anti-EBNA-1 and anti-
VCA, respectively.
In the combined group of controls, levels of anti-
EBNA-1 and especially anti-VCA were substantially and
significantly lower with three cKS cofactors: male sex,
nonsmoking, and diabetes (Table 3). The anti-EBNA-1
and anti-VCA levels also were marginally lower with the
fourth cKS cofactor, cortisone use (Table 3).
All sCD26, sCD23 and sCD30 levels were within
detectable limits. Medians and interquartile ranges were
similar across groups (cKS cases, KSHV seropositives,
and seronegatives), and no significant differences were
found (P≥0.35, data not presented).
Considering cKS cofactors in the control subjects,
sCD26 levels were higher in females (median 459 ng/mL
vs 416 ng/mL, Padj = 0.006) and current smokers versus
never smokers (median 508 ng/mL vs 425 ng/mL, Padj =
0.03); and sCD26 levels tended to be lower in cortisone
users (median 422 ng/mL vs 446 ng/mL, Padj = 0.09).
Older controls tended to have lower sCD26 (Padj = 0.06)
and higher sCD30 (Padj = 0.08) levels. Otherwise, cKS
cofactors were not associated with sCD levels (Padj >
0.09, data not presented).
Discussion
Cases of cKS did not differ from KSHV-seropositive
controls in anti-EBV or sCD levels. Ap o s t e r i o r i ,w e
Table 1 Distribution of classical Kaposi sarcoma (cKS) cofactors among current study subjects and among all controls
in the parent study, KCC-2
cKS cases Seropositive controls Seronegative controls All KCC-2 controls
N (%) n % n % n %
Sex
Male 76 (64%) 72 (69%) 100 (65%) 848 (73%)
Female 43 (36%) 33 (31%) 55 (35%) 306 (27%)
Smoking Status
Never
Former
Current
58
51
10
(49%)
(43%)
(8%)
42
44
19
(40%)
(42%)
(18%)
70
64
21
(45%)
(41%)
(14%)
439
519
196
(38%)
(45%)
(17%)
Diabetes
Yes
No
36
83
(30%)
(70%)
14
91
(13%)
(87%)
44
111
(28%)
(72%)
202
952
(18%)
(82%)
Cortisone use*†
Yes
No
42
77
(35%)
(65%)
18
87
(17%)
(83%)
40
113
(26%)
(73%)
293
857
(25%)
(74%)
mean range mean range mean range mean range
Age 75 49-94 73 39-91 73 38-91 71 32-92
*During the last 10 years.
†Percentages may equal less than 100 due to missing data.
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cantly associated with low anti-EBNA-1 and especially
low anti-VCA. Levels of sCD26 tended to be lower in
older controls and cortisone users, and they were signifi-
cantly lower in never smokers and males.
Our assays have been used as measures of immunity
for epidemiologic research, specifically invoking the Th1/
Th2 cellular immunity paradigm [9,10,16]. However, in
vitro data to support their use are sparse. Especially with
a single plasma sample, these assays may be too crude to
distinguish a chronic condition, such as cKS, with the
limited statistical power that we had herein.
Although cases did not differ from controls, our find-
ings on cKS cofactors among controls should be noted,
particularly because these cofactors are also associated
with Th1/Th2 alteration. Th1 responses are generally
lower and Th2 responses generally higher in women,
smokers, diabetics, and corticosteroid users [17-22].
Classical KS risk is increased for corticosteroid users
and perhaps diabetics, but cKS risk is reduced for
women and smokers [15,23]. The effect of smoking on
Th1/Th2 cytokine levels may also differ by sex [24].
These complex and even inverse relationships suggest
that differences in cKS risk may reflect differences in
Table 2 Risk of classical Kaposi sarcoma (cKS) or KS-associated herpesvirus (KSHV) seropositivity by Epstein Barr virus
(EBV) antibody category
EBV antibody tertile category
Cases
N (%)
119
Seropositive controls
N (%)
105 ORadj* (95% CI) HRadj** (95% CI)
Low EBNA-1 43 (36%) 34 (32%) 0.97 (0.52 – 1.82) 0.93 (0.45 – 1.98)
High VCA 42 (35%) 45 (43%) 0.87 (0.45 – 1.69) 1.10 (0.50 – 2.35)
Low EBNA-1/high VCA 5 (4%) 6 (6%) 0.55 (0.15 – 2.00) 0.53 (0.12 – 2.29)
EBNA-1/VCA category
Low/High
Low/Not high
Not low/High
Not low/not high
5 (4%)
38 (32%)
37 (31%)
39 (33%)
6 (6%)
28 (27%)
39 (37%)
32 (30%)
0.56 (0.14 – 2.18)
1.08 (0.52 – 2.25)
0.98 (0.46 – 2.09)
Reference
0.62 (0.13 – 3.10)
1.20 (0.49 – 2.92)
1.23 (0.54 – 2.84)
Reference
EBV antibody tertile category
Seropositive controls
N (%)
105
Seronegative controls
N (%)
155 ORadj† (95% CI) HRadj‡ (95% CI)
Low EBNA-1 34 (32%) 52 (34%) 0.98 (0.56 – 1.70) 1.04 (0.60 – 1.80)
High VCA 45 (43%) 42 (27%) 1.90 (1.04 – 3.47) 1.88 (1.04 – 3.40)
Low EBNA-1/high VCA 6 (6%) 6 (4%) 1.53 (0.47 – 5.02) 1.00 (0.33 – 3.07)
EBNA-1/VCA category
Low/High
Not low/High
Low/Not high
Not low/not high
6 (6%)
28 (27%)
39 (37%)
32 (30%)
6 (4%)
46 (30%)
36 (23%)
67 (42%)
2.11 (0.61 – 7.30)
1.18 (0.61 – 2.27)
2.02 (1.00 – 4.07)
Reference
1.76 (0.52 – 5.93)
1.43 (0.74 – 2.78)
2.20 (1.14 – 4.24)
Reference
*Adjusted odds ratio (ORadj) comparing cases to KHSV seropositive controls with logistic regression (adjusted for age group, sex, smoking, diabetes, cortisone use).
**Adjusted hazard ratio (HRadj) comparing cases to seropositive controls using conditional logistic regression (adjusted for age group, sex, smoking, diabetes and
cortisone, and conditioning on assay batch).
†Adjusted odds ratio (ORadj) comparing all tested KSHV seropositive controls to seronegative controls with logistic regression models (adjusted for matching.
factors: age group, sex, smoking and diabetes).
‡Adjusted hazard ratio (HRadj) comparing matched KSHV seropositive and seronegative controls using conditional logistic regression (conditioning on matched
set and assay batch).
Table 3 Differences in Epstein Barr virus (EBV) antibody
levels among controls, by risk factors for classical Kaposi
sarcoma
mean difference*
(95% CI)
Cofactor EBNA-1 VCA
Age, continuous 0.00 (-0.02 to 0.02) 0.02 (0.00 to 0.04)
Sex
Male
Female
-1.21 (-1.78 to -0.64)
Reference
-2.14 (-2.67 to -1.62)
Reference
Smoking status
Never
Former
Current
-0.62 (-1.30 to 0.07)
-0.82 (-1.41 to -0.23)
Reference
-2.37 (-3.01 to -1.73)
-1.09 (-1.64 to -0.54)
Reference
Diabetes
Yes
No
-0.82 (-1.29 to -0.34)
Reference
-0.84 (-1.29 to -0.40)
Reference
Cortisone use in last 10 years
Yes
No
-0.41 (-0.89 to 0.06)
Reference
-0.46 (-0.89 to -0.02)
Reference
KSHV antibody status
Positive
Negative
0.18 (-0.22 to 0.59)
Reference
0.11 (-0.27 to 0.49)
Reference
*Mean difference from multivariate linear regression models that included all
variables shown.
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weakly, by anti-EBV and sCD26 levels.
In summary, anti-EBV and sCD26 levels were associated
with cofactors for cKS, but not with cKS risk per se. Per-
haps Th1/Th2 imbalance is poorly measured by these
assays or is unrelated to cKS risk. Further studies of cKS
risk with a more comprehensive panel of cytokine and
inflammatory markers will be needed to illuminate the
abnormalities that contribute to this malignancy.
Methods
The parent case-control study, including KSHV serostatus
definition, has been reported [15]. The current study
included all cKS cases, all KSHV-seropositive controls,
and a sample of KSHV-seronegative controls with ≥0.5
mL previously unthawed plasma for the assays. Seronega-
tives were matched to seropositive controls and cases on
cKS cofactors (sex, age group, cigarette smoking and
diabetes).
EBV enzyme immunoassays were performed as
described [25]. Antibody levels were the ratio of each spe-
cimen’s average optical density (OD450) divided by the
average OD450, plus 2 standard deviations, of four negative
controls on each plate. Ratio value is highly correlated
with anti-EBV immunofluorescence end-point titer [25].
Commercial kits were used to quantify sCD26, sCD23 and
sCD30 [Bender MedSystems GmbH (Vienna, Austria)].
Three sets of comparisons were made: cKS cases
versus KSHV-seropositive controls; KSHV-seropositive
versus-seronegative controls; and all controls by cKS-
related cofactors (including KSHV serostatus). We used
linear regression (for anti-EBV levels) or Mann-Whit-
ney-Wilcoxon (for sCD levels) methods. As done pre-
viously [8,9], cKS risk was postulated to be highest with
low-EBNA-1/high-VCA, defined using tertiles among
controls. Odds of cKS was estimated with unconditional
logistic regression and with conditional logistic regres-
sion, conditioning on assay batch.
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